The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Regarding General Meeting

2 Sep 2014 07:00

RNS Number : 5692Q
Plethora Solutions Holdings PLC
02 September 2014
 



 

 

2 September 2014

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

 

Further Regarding General Meeting

 

 

Further to the announcement made on 29 August 2014, Plethora Solutions Holdings plc (AIM: PLE) announces that the Company has posted a new Notice of General Meeting to Shareholders, which is intended to be in substitution for that attached to the Circular letter dated 29 August 2014. The new Notice of General Meeting to Shareholders will be made available on the Company's website, www.plethorasolutions.co.uk.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die. Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting to be held on 18 September 2014.

 

All terms defined in that letter dated Friday, 29 August 2014 have the same meaning when used in this announcement. Shareholders and investors should read the whole text of this announcement.

 

 

Background

 

The Chairman of the Company wrote to Shareholders on Friday, 29 August 2014 in order, inter alia, to convene a General Meeting of shareholders to pass the necessary shareholders resolutions to approve the matters referred to in that Circular letter.

 

Unfortunately, the Notice of General Meeting attached to that Circular letter contained some minor printing errors. Because the Notice of General Meeting is a formal document, it is necessary to issue a new Notice of General Meeting intended to be in substitution for that attached to the Circular letter dated 29 August 2014.

 

Accordingly, a new Notice of General Meeting in which the printing errors have been corrected together with a replacement proxy card for use in relation to the Notice of General Meeting has been sent to Shareholders.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die.

 

Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

 

Action to be Taken

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting. Whether or not Shareholders intend to attend the replacement General Meeting Shareholders are requested to complete the replacement Form of Proxy in accordance with the instructions printed on it and to return it to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, as soon as possible, and in any event so as to arrive no later than 10:00am on 16 September 2014.

 

If Shareholders hold their Ordinary Shares in CREST they may appoint a proxy using the CREST proxy appointment service by following the instructions in note (6) to the replacement Notice of General Meeting. The completion and return of a Form of Proxy, or the electronic appointment of a proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

 

 

Recommendation

 

The Directors believe that the Placing & Subscription, and therefore the Resolutions set out in the replacement Notice of General Meeting, are in the best interests of the Company and Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote in favour of those Resolutions, as they intend to do in respect of their own shareholdings, which in aggregate total 131,949,742 Ordinary Shares representing approximately 31.8% of the existing issued ordinary share capital of the Company.

 

-Ends-

 

Enquiries:

Plethora Solutions

Jim Mellon, Chairman

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

Greg Bailey, NXD

 

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

Emma Earl / Alex Brearley (Nomad)

Martin Lampshire (Broker)

 

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

Niall Pearson

 

Tel: +44(0) 20 3713 4581

Tel: +44(0) 20 3713 4582

Tel: +44(0) 20 3713 4583

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

 

About PSD502™ & Premature Ejaculation:

 

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURUAOURSVAKRUR
Date   Source Headline
17th Nov 20107:00 amRNSChange of Adviser
10th Nov 20102:27 pmRNSHolding in Company
7th Sep 20107:00 amRNSHalf Yearly Report
29th Jul 20102:27 pmRNSHolding(s) in Company
23rd Jul 201010:55 amRNSHolding(s) in Company
19th Jul 20107:00 amRNSNew Product Launch
13th Jul 20107:00 amRNSPre-close Trading Update
30th Jun 20107:00 amRNSTerm Loan Agreement
10th Jun 201012:06 pmRNSLTIP Awards
2nd Jun 20107:00 amRNSAmerican Urological Association Showcase
27th May 20109:27 amRNSResult of AGM
17th May 20107:00 amRNSCommercial Update - The Urology Company
6th May 20107:00 amRNSAnnual Report and Accounts
5th May 20107:00 amRNSIssue of Equity
12th Apr 20107:00 amRNSExclusive Distribution Agreement
9th Mar 20107:00 amRNSPreliminary Results
24th Feb 20103:31 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSNotice of Results
19th Jan 20107:00 amRNSPre-Close Trading Update
14th Dec 20095:23 pmRNSHolding(s) in Company
7th Dec 200911:23 amRNSResult of EGM
30th Nov 20097:00 amRNSExclusive License and Distribution Agreement
23rd Nov 20097:00 amRNSExclusive License and Distribution Agreement
19th Nov 20094:23 pmRNSDirector/PDMR Shareholding
18th Nov 20097:23 amRNSPlacing and Convertible Loan Note
30th Sep 20097:00 amRNSClinical Update re: PSD506
17th Sep 20097:00 amRNSInterim Results
7th Aug 20094:42 pmRNSHolding(s) in Company
5th Aug 200910:42 amRNSHolding(s) in Company
29th Jul 20097:00 amRNSFinal Phase III Pivotal Trial Results PSD502
16th Jul 20097:00 amRNSPSD503 Update - Evaluation and Option Agreement
25th Jun 20091:57 pmRNSAGM Statement and Trading Update
15th Jun 20093:57 pmRNSHolding(s) in Company
29th May 20093:34 pmRNSAnnual Report and Accounts and AGM Notice
26th May 20097:05 amRNSDirectorate Change
26th May 20097:00 amRNSGlobal Agreement, Restructuring and Final Results
1st Apr 20097:00 amRNSUpdate re: PSD502
19th Feb 20097:00 amRNSDirectorate Change
18th Feb 20099:24 amRNSClinical Update PSD502
16th Feb 200911:31 amRNSLoan Agreement and US License Amendment
16th Feb 200911:26 amRNSResult of General Meeting
22nd Jan 20097:00 amRNSFunding Update and Notice of GM
23rd Dec 20084:17 pmRNSHolding(s) in Company
18th Dec 200811:55 amRNSHolding(s) in Company
11th Dec 20089:12 amRNSHolding(s) in Company
8th Dec 20087:00 amRNSIssue of Equity
8th Dec 20087:00 amRNSClinical Update: PSD502
14th Nov 20087:00 amRNSHolding(s) in Company
14th Nov 20087:00 amRNSErecAid Study Results
7th Nov 20087:00 amRNSPhase III European Clinical Trial Results PSD502

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.